Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4Prostatic Neoplasms 2Neoplasm Metastasis 2With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Smoldering Multiple Myeloma 1Osteoporosis 1Multiple Myeloma 1Melanoma 1Mastocytosis, Systemic 1Giant Cell Tumor of Bone 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 69atezolizumab 54lenvatinib 42durvalumab 42Nivolumab 38pembrolizumab 35tremelimumab 28Magnetic Resonance Spectroscopy 21Specimen Handling 19tislelizumab 18sintilimab 17Ipilimumab 15Sorafenib 14regorafenib 13cabozantinib 13Radiosurgery 13Radiotherapy 12apatinib 11Blood Specimen Collection 11Immunoglobulin G 10camrelizumab 9Immune Checkpoint Inhibitors 9Disulfides 9X-Rays 8Cyclophosphamide 8donafenib 7Oxaliplatin 7Immunotherapy 7Folfox protocol 7Fluorouracil 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Denosumab × 1 year × Clear all
NCT07537972 2026-04-17

Denosumab Strategy for Liver Cancer With Bone Metastases

Tongji Hospital

Phase 2 Not yet recruiting
50 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡